Prediction Market Odds: FDA approves skin cancer vaccine by...?

  • December 31, 202762.5%
  • June 30, 202714%

Questions and Answers

Can't find the answer you need? Contact us and we'll respond promptly.

It is a Politics prediction market where you back the outcome you expect for “FDA approves skin cancer vaccine by...?”. The odds move in real time with news and demand, and the market settles once the outcome is confirmed under its rules.

December 31, 2027 is currently the likeliest outcome at 62.5%. The figure updates live, so check the market for the latest odds before you decide.

The market is scheduled to end on January 1, 2028. Its rules explain exactly how and when it settles, so read them on the market page before you take a position.

Create an account, fund it with crypto, then open the market and pick your outcome. Confirm your stake in the bet slip and follow the odds until the market settles. If you are new, our complete user guide for new players walks through each step.

No. 62.5% is the crowd's current estimate, not a prediction that is certain to come true, and any outcome can lose. Treat prediction markets as entertainment, set limits before you play and read our tips for staying in control if you want help keeping your play healthy.

December 31, 2027 is currently the likeliest outcome for “FDA approves skin cancer vaccine by...?” at 62.5%. Pick your side and follow the odds live until the market is scheduled to end on January 1, 2028.

Prediction Market Odds: FDA approves skin cancer vaccine by...?

Bet on the Outcome: FDA approves skin cancer vaccine by...?

The “FDA approves skin cancer vaccine by...?” market is open on BiggerZ, and December 31, 2027 is currently the likeliest outcome at 62.5%. Odds reflect what the crowd expects right now and move as news breaks, so the picture can change quickly. The market is scheduled to end on January 1, 2028. Pick the outcome you believe in, follow the live odds, and manage everything from the BiggerZ crypto-first betting platform, where the same account also opens the online casino.

Want to compare? Explore more prediction markets on BiggerZ.

What Is the “FDA approves skin cancer vaccine by...?” Market?

This is a Politics prediction market: a live market built around one question about a real-world event. You back the outcome you think is most likely, and the odds show how the crowd rates each option at the moment. Each market follows its own resolution rules, which state what counts as a result and when the market settles.

How to Read the Odds

Right now, December 31, 2027 leads at 62.5%. Read that figure as the crowd's current estimate of how likely the outcome is, not as a promise. A higher percentage means the crowd sees the outcome as more likely, and a lower one means it sees it as less likely. The numbers shift whenever new information changes expectations, so the favorite today may not be the favorite next week.

How to Trade the “FDA approves skin cancer vaccine by...?” Market

  1. Check the odds. See who or what leads and how the other outcomes compare.
  2. Pick your outcome. Back the one you expect.
  3. Follow the market. Watch the odds move live as the story develops.
  4. Wait for the result. The market settles once the outcome is confirmed under its rules.

New to the format? Read about how prediction markets launched on BiggerZ, or follow our beginner's guide to getting started from sign-up to your first bet.

What Could Move the Odds

  • News and announcements. Official statements, results and breaking stories can shift expectations within minutes.
  • Data and scheduled events. Releases, votes, deadlines and meetings often act as turning points.
  • Public sentiment. As more people take a side, the odds adjust to reflect the crowd.
  • The end date. The market is scheduled to end on January 1, 2028, and the odds tend to sharpen as that date gets closer. Always check the market rules for exactly how and when it settles.

Why Follow This Market on BiggerZ?

One Account, Every Product

Prediction markets, the sportsbook and the casino share one wallet. Between checking on “FDA approves skin cancer vaccine by...?”, you can jump into crypto casino games without starting over.

Built for Crypto

Fund your account with major coins and stablecoins, which suits markets that are themselves tied to digital assets.

Rewards That Carry Across

Check our promotions to see which offers are live, and join the BiggerZ VIP program for tiered perks as your activity grows. Always read each offer's terms to confirm whether it applies to prediction markets.

When You Want a Change of Pace

While the odds move, the rest of the platform is a click away. Spin crypto slots, sit at a table in the live dealer casino, or try our original casino games. See what players are enjoying right now in popular casino games, discover the latest casino games, compare payouts with the live RTP tracker, or compete for a prize pool in our casino tournaments.

Predict Responsibly

The “FDA approves skin cancer vaccine by...?” market is entertainment, not a guaranteed source of income, and no amount of research removes the risk of losing. Set a budget before you start, and only stake what you can afford to lose. Our responsible gambling tips explain how to set limits and spot the warning signs. You must be 18 or older, and availability depends on your country of residence.

About FDA approves skin cancer vaccine by...?

Listed on BiggerZ August 20, 2026 · Ends January 1, 2028 · Volume $312.3K (Polymarket)

Politics, Tech

Outcomes and odds

OutcomeChanceOdds
December 31, 202762.5%1.43
June 30, 202714%6.38

Resolution rules

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above. Approval as part of a combination regimen will qualify. Approval for a narrower population than the one studied in INTerpath-001 will qualify. Approval for an indication other than melanoma will also qualify. Both standard and accelerated approval will qualify. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Act (PDUFA) dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source for this market will be official information from the FDA; however, a consensus of credible reporting may also be used.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above. Approval as part of a combination regimen will qualify. Approval for a narrower population than the one studied in INTerpath-001 will qualify. Approval for an indication other than melanoma will also qualify. Both standard and accelerated approval will qualify. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Act (PDUFA) dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source for this market will be official information from the FDA; however, a consensus of credible reporting may also be used.